Notwithstanding positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant difficulty from managed care entities. Such insurers are frequently erecting obstacles to access, including steep expense restrictions and prior authorization that limit user opportunity. Market